A Nose-Delivered Vaccine May Help End Deadly Tuberculosis Outbreaks

A dedicated research team at Johns Hopkins Medicine is developing an innovative intranasal vaccine to combat tuberculosis, the world’s leading infectious disease killer. This new approach targets drug-tolerant bacteria that often survive standard antibiotic treatments and cause future relapses.

By fusing two specific genes, the vaccine trains the immune system to recognize and attack the bacteria where they are most vulnerable. This method aims to shorten treatment times and improve recovery for millions of patients worldwide.

Quick Smiles:

• The vaccine uses DNA fusion to attract specialized immune cells for a targeted attack on stubborn bacteria.
• Testing showed the treatment generates long-lasting immunity in both the lungs and the bloodstream.
• Scientists believe the DNA-based design could be easier to manufacture and distribute globally.

Researchers found that administering the vaccine through the nose helps clear infection faster while significantly reducing lung inflammation. This localized delivery creates a strong immune memory directly in the airways where the infection typically begins.

“Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster,” says study lead author Styliani Karanika, MD.

“The vaccine also helped the powerful TB drug combination work better, suggesting it could be used against drug-resistant TB to help the body fight the disease.”

The study also showed promising results in primate models, demonstrating durable immune responses that lasted for at least six months. These findings provide a vital bridge toward future human trials and more effective global treatments.

This breakthrough represents a major step forward in the effort to end the tuberculosis epidemic through modern immunotherapy. By combining traditional medicine with this high-tech vaccine, doctors hope to finally outpace drug-resistant strains.

Source